Scilit logo
  • Rankings
  • Search Publications
    Cited-by Search
  • Sources
  • Publishers
  • Scholars
    Top Cited Scholars
  • Organizations
  • Scilit
    About Us
    Advisory Board
    Data Sources
    Career
    Support / Contact
    User Guide
    Publisher User
    Search Function
    Rankings Function
    API Resource
    Scilit Knowledge
    Metrics
    Scilit Recognitions
    Publications Classification
    Media
    News
    Blog
Register
  1. Home
  2. Publications
  3. Supplementary Figure S4 from Derivation of AZD5335, a Novel FRα-Targeted TOP1i-Loaded ADC, for the Treatment of FRα-Expressing Cancers
  1. Home
  2. Publications
  3. Supplementary Figure S4 from Derivation of AZD5335, a Novel FRα-Targeted TOP1i-Loaded ADC, for the Treatment of FRα-Expressing Cancers

Supplementary Figure S4 from Derivation of AZD5335, a Novel FRα-Targeted TOP1i-Loaded ADC, for the Treatment of FRα-Expressing Cancers

Authors:
  • JZJason J. Zoeller
    Jason J. Zoeller
  • RTRavinder Tammali
    Ravinder Tammali
  • RDRoger B. Dodd
    Roger B. Dodd
  • NPNeki V. Patel
    Neki V. Patel
  • AAAlma Andoni
    Alma Andoni
  • IBIna Bisha
    Ina Bisha
  • SCShane Cronin
    Shane Cronin
  • AAAna De Almeida
    Ana De Almeida
  • NLNancy Lee
    Nancy Lee
  • JMJohn H. Meekin
    John H. Meekin
  • ITIsabella Tilmont
    Isabella Tilmont
  • DGDiana Gasper
    Diana Gasper

Open Access
Publisher website
Google Scholar
  • 15 December 2025
    • other
    • Published by American Association for Cancer Research (AACR)
    • DOI:10.1158/1078-0432.30883060
Abstract
Assessment of AZD5335-associated bystander activities.
Keywords
  • BIOLOGICAL AGENTS & THERAPIES
  • ANTIBODY-DRUG CONJUGATES
  • GYNECOLOGICAL CANCERS
  • OVARIAN CANCER
Scilit logo

Have questions? Email us at support@scilit.com

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.

MDPI initiatives

  • MDPI Journals
  • MDPI Books
  • Sciforum
  • Proceedings Series
  • Preprints.org
  • SciProfiles
  • Encyclopedia
  • JAMS

Legal

  • Privacy
  • Terms
  • About
  • Contact
  • Disclaimer

Follow us

  • facebook icon
  • x icon
  • linkedin icon

Join us

  • Career

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.